Dose the first patient with rBCG in the United States
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Mar 2025
- Due
- 31 Mar 2025
- Delivered
- 13 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The first patient dosed with rBCG in the United States is anticipated in March 2025.”
What we found
Evidence strength A What the grades mean
ImmunityBio announced first patient dosing with rBCG in the U.S. on March 13, 2025, meeting the March 2025 deadline.
-
A Press Release dated March 3, 2025
“The first patient dosed with rBCG in the United States is anticipated in March 2025.” ✓ confirmed on the page
-
B ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites in the Process of Launching
“CULVER CITY, Calif., March 13, 2025 – ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners” ✓ confirmed on the page
-
D ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
“U.S. Urology Partners is one of the first providers to offer patients ImmunityBio's recombinant Bacillus Calmette-Guérin (rBCG).”
Checked 7 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- first patient dosed with rBCG
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-IBRX-002822 · Corrections policy